-
-
-
-
-
-
-
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
-
-
-
-
-
-
-
Valerio Therapeutics Reports its Half-Year 2024 Financial Results and Provides an Update on its Activities
-
-
-
-
-
-
-
Bio-Rad Reports Second-Quarter 2023 Financial Results
-
-
-
-
-
-
-
Bio-Rad Reports Second-Quarter 2022 Financial Results
-
-
-
-
-
-
-
Bio-Rad Reports First-Quarter 2021 Financial Results
-
-
-
-
-
-
-
S&P Dow Jones Indices Announces Tyler Technologies, Bio-Rad Laboratories and Teledyne Technologies Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
-
-
-
-
-
-
-
Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance
-
1,154,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

